NYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $250.52 -1.31 (-0.52%) Closing price 11/2/2026 03:59 PM EasternExtended Trading$249.91 -0.61 (-0.24%) As of 08:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Quest Diagnostics Stock (NYSE:DGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$247.71▼$251.9850-Day Range$226.94▼$252.9352-Week Range$171.18▼$256.99Volume996,286 shsAverage Volume1.05 million shsMarket Capitalization$27.56 billionP/E Ratio22.25Dividend Yield1.37%Price Target$248.70Consensus RatingModerate Buy Company Overview Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services. Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers. Through its laboratory network, patient service centers and digital tools, the company supports clinical decision-making, preventive care, wellness programs and occupational health services. It also provides drug testing and other workforce-related testing programs. The company traces its origins to the clinical laboratory operations of Corning Incorporated and became an independent public company in 1996 before adopting the Quest Diagnostics name. Its operations are primarily based in the United States, with services delivered through facilities and collection locations across the country. Quest Diagnostics is led by Chief Executive Officer Jim Davis.AI Generated. May Contain Errors. Read More Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreDGX MarketRank™: 3.84519596277 of 5 starsQuest Diagnostics scored higher than 77% of companies evaluated by MarketBeat, and ranked 190th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageQuest Diagnostics has only been the subject of 4 research reports in the past 90 days.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.31% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 5.31% in the coming year, from $11.29 to $11.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 22.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 22.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 38.45.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.27% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quest Diagnostics has recently increased by 4.57%, indicating that investor sentiment is decreasing. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.40%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 34.26%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 28.93% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. News and Social Media3.5 / 5News Sentiment0.67 News SentimentQuest Diagnostics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Quest Diagnostics this week, compared to 6 articles on an average week.Search Interest7 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,232,534.00 in company stock.Percentage Held by Insiders0.88% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGX Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Annexon Biosciences (ANNX), Resmed (RMD) and Quest Diagnostics (DGX)November 2 at 6:15 AM | theglobeandmail.comQuest Diagnostics (NYSE:DGX) Stock: Insider Gary Pfeiffer Sells 1,203 SharesOctober 29, 2026 | insidertrades.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 3 at 1:00 AM | Behind the Markets (Ad)Evercore ISI Adjusts Price Target on Quest Diagnostics to $240 From $235October 28, 2026 | marketscreener.comMRothschild & Co Redburn Adjusts Price Target on Quest Diagnostics to $279 From $251October 27, 2026 | marketscreener.comMQuest Diagnostics Upgraded After Strong Q3, While Also Announcing New Test For Alzheimer'sOctober 26, 2026 | seekingalpha.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), Quest Diagnostics (DGX) and Argenx Se (ARGX)October 24, 2026 | theglobeandmail.comQuest Diagnostics (DGX) Stock Price Stalls After Strong Q3 EarningsOctober 24, 2026 | finance.yahoo.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $173.47 on January 1st, 2026. Since then, DGX stock has increased by 44.4% and is now trading at $250.5150. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) posted its earnings results on Thursday, October, 22nd. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.87 by $0.13. The company's revenue for the quarter was up 10.0% on a year-over-year basis. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors initiated a stock buyback plan on Tuesday, February 10th 2026, which authorizes the company to repurchase $1 billion in shares, according to EventVestor. This means that the company could purchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an IPO on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Top institutional shareholders of Quest Diagnostics include Sumitomo Mitsui Trust Group Inc. (0.23%), Eastern Bank (0.19%), Conning Inc. (0.15%) and Robeco Institutional Asset Management B.V. (0.11%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include Pfizer (PFE), NVIDIA (NVDA), Qualcomm (QCOM), AbbVie (ABBV), Johnson & Johnson (JNJ), Tesla (TSLA) and Walmart (WMT). Company Calendar Record date for 10/21 Dividend10/06/2026Ex-Dividend for 10/21 Dividend10/06/2026Dividend Payable10/21/2026Last Earnings10/22/2026Today11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DGX's financial health is in the Green zone, according to TradeSmith. DGX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees57,000Year Founded1967Price Target and Rating Average Price Target for Quest Diagnostics$248.70 High Price Target$262.00 Low Price Target$215.00 Potential Upside/Downside-0.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$10.04 Trailing P/E Ratio22.25 Forward P/E Ratio21.07 P/E Growth2.2Net Income$992 million Net Margins9.53% Pretax Margin12.60% Return on Equity16.21% Return on Assets7.41% Debt Debt-to-Equity Ratio0.70 Current Ratio1.70 Quick Ratio1.58 Sales & Book Value Annual Sales$11.04 billion Price / Sales2.50 Cash Flow$15.47 per share Price / Cash Flow16.19 Book Value$72.26 per share Price / Book3.47Miscellaneous Outstanding Shares110,020,000Free Float109,051,000Market Cap$27.56 billion OptionableOptionable Beta0.54 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:DGX) was last updated on 11/2/2026 by MarketBeat.com Staff. From Our PartnersxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again un...USA Capital Gold | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
